EpCAMx4-1BB demonstrates conditional agonistic and antitumor activity

Oct. 31, 2023

Researchers from Biontech SE and Genmab BV presented the discovery and preclinical evaluation of a novel Duobody-EpCAMx4-1BB (BNT314/GEN1059), a novel Fc-inert immunomodulatory bispecific antibody (bsAb) designed to boost antitumor immune responses through EpCAM-dependent 4-1BB agonistic activity.

BioWorld Science Conferences European Society for Medical Oncology Cancer Bispecific antibody Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for Nov. 26, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 26, 2024.

J&J’s Ottava robotic system approved for US pivotal trial

BioWorld MedTech

Johnson & Johnson received U.S. FDA investigational device exemption to begin the pivotal clinical trial for the Ottava robotic surgical system. If the trial goes...

Illustration of man holding magnifying glass to human body model showing muscle anatomy

In muscular dystrophies, gene therapies race the clock

BioWorld

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...

‘Evo’ AI can design complete genomes

BioWorld Science

The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

Upgrade your daily dose of biopharma and medtech news

EpCAMx4-1BB demonstrates conditional agonistic and antitumor activity